The apnea-hypopnea index (AHI) is a scale that tells whether you have a sleep disorder called apnea and, if so, how serious it is. Sleep apnea is when you stop breathing for 10 seconds or more ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Consumer Reports has no financial relationship with any advertisers on this site. When you have obstructive sleep apnea, addressing it is key. Left untreated, sleep apnea is linked to daytime ...

You can sometimes find an AHI display on your machine or monitoring apps. Using a CPAP machine can improve your AHI. If your AHI does not get better with the use of a CPAP machine, talk to your ...

Home sleep apnea tests (HSATs) use sophisticated sensors and algorithms to monitor your breathing patterns, oxygen levels, ...

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Each sleep apnea severity group — AHI less than 5 (no sleep apnea), AHI of 5 or greater but less than 30 (mild to moderate sleep apnea) and AHI of 30 or higher (severe sleep apnea ...

Evaluating AD109’s Results For phase II trials, patients were separated into groups after they were tested to see how severe their sleep apnea was, using the apnea-hypopnea index (AHI).

Reducing body weight with tirzepatide (Zepbound; Eli Lilly) decreases how often sleep is disrupted for patients who have moderate-to-severe obstructive sleep apnea (OSA) and obesity, results from the ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...